Journal: BMC Cancer

Article Title: ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

doi: 10.1186/1471-2407-8-97

Figure Lengend Snippet: A sensitivity index of 0 indicates maximal drug sensitivity, whereas a sensitivity index of 600 reflects minimal drug sensitivity. Relative ERCC1 mRNA expression (logarithmically transformed) was positively correlated with resistance to cisplatin in 19 NSCLC patients (P = 0.001, r = 0.685).

Article Snippet: Assay IDs: Hs00157415_m1 (ERCC1); Hs00173233_m1 (BRCA1); Hs99999903_m1(β-actin)), 1× Absolute QPCR Mix (ABgene, Surrey, UK).

Techniques: Expressing, Transformation Assay

Journal: BMC Cancer

Article Title: ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

doi: 10.1186/1471-2407-8-97

Figure Lengend Snippet: ERCC1 mRNA expression levels were significant association with sensitivity to cisplatin in 12 untreated gastric cancer patients (P = 0.014, r = 0.685).

Article Snippet: Assay IDs: Hs00157415_m1 (ERCC1); Hs00173233_m1 (BRCA1); Hs99999903_m1(β-actin)), 1× Absolute QPCR Mix (ABgene, Surrey, UK).

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: Hsa_circ_0001946 Inhibits Lung Cancer Progression and Mediates Cisplatin Sensitivity in Non-small Cell Lung Cancer via the Nucleotide Excision Repair Signaling Pathway

doi: 10.3389/fonc.2019.00508

Figure Lengend Snippet: hsa_circ_0001946 mediated cisplatin resistance via the NER signaling pathway (A) . The IC 50 values of cisplatin in A549 and A549/DDP cell lines (B) . The IC 50 value of cisplatin after transfection of A549 cells with hsa_circ_0001946 siRNA. The hsa_circ_0001946 group exhibited a higher IC 50 value of cisplatin than the negative control group (C) . Cell proliferation was evaluated by EDU assay after siRNA transfection and treatment with 15 μM cisplatin (D) . Apoptosis of cells was assessed by Hoechst assay after siRNA transfection and treatment with 15 μM cisplatin (E) . Representative flow cytometry results showing that the effects of hsa_circ_0001946 on cisplatin decreased cell apoptosis in the A549 cell line (F) . Cell viability was also evaluated by dye exclusion assay using flow cytometry after siRNA transfection and treatment with 15 μM cisplatin (G) . HCR analysis of UV damaged pCMV plasmid (H) . The damaged pCMV plasmids were then transfected into scrambled control or hsa_circ_0001946 silenced cells followed by analysis of luciferase activity. HCR results showed increased DNA damage repair in siRNA transfection group (I) . The expression of the NER pathway-associated proteins, XPA, XPC, Rad23B, RPA14, RPA32, RPA70, and ERCC1 was detected by western blotting after siRNA transfection (All data are presented as the mean ± SEM, * P < 0.05, ** P < 0.01, *** P < 0.001).

Article Snippet: After 2 h of blocking, PVDF membranes were incubated with antibodies against β-actin (Sigma-Aldrich), AKT, P-AKT, Bcl-2, Bax, caspase 3, cleaved caspase 3, p53, EGFR, replication protein A 32 (RPA32) (Wanleibio, Shenyang, China), xeroderma pigmentosum complementation group A (XPA), xeroderma pigmentosum complementation group C (XPC), RPA70, radiation sensitive 23 homolog B (Rad23B) (Proteintech, Rosemont, IL), RPA14 (Omnimabs, Alhambra, CA), RPA70 (Abcam, Cambridge, UK), and ERCC excision repair 1 (ERCC1) (Cell Signaling Technology, Boston, USA) overnight at 4°C.

Techniques: Transfection, Negative Control, EdU Assay, Flow Cytometry, Exclusion Assay, Plasmid Preparation, Control, Luciferase, Activity Assay, Expressing, Western Blot

Journal: Lung Cancer

Article Title: Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair

doi: 10.2147/LCTT.S57594

Figure Lengend Snippet: Summary of DNA repair genes analyzed with their average fold changes and P -values

Article Snippet: ERCC1 , Hs01012158_m1 , 0.76 , 0.0644 , 9↓.

Techniques: Homologous Recombination

Journal: Molecular Medicine Reports

Article Title: MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5-fluorouracil in MEK1 Q56P-mutant colorectal cancer cells

doi: 10.3892/mmr.2018.9730

Figure Lengend Snippet: Gene expression induced by U0126 combined with or without oxaliplatin/5-FU. (A) ERCC1 mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or 5-FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β-actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5-FU, respectively. **P<0.01 vs. control group; ## P<0.01 vs. oxaliplatin/5-FU-treated group. 5-FU, 5-fluorouracil; ERCC1, excision repair cross-complementation group 1; TYMS, thymidylate synthase; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

Article Snippet: Excision repair cross-complementation group 1 (ERCC1) rabbit polyclonal antibody (cat. no. 14586-1-AP) and TYMS rabbit polyclonal antibody (cat. no. 15047-1-AP) were purchased from ProteinTech Group, Inc. (Wuhan, China).

Techniques: Gene Expression, Quantitative RT-PCR, Standard Deviation, Western Blot, Expressing, Control, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: ESMO Open

Article Title: Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial

doi: 10.1016/j.esmoop.2021.100249

Figure Lengend Snippet: Consolidated Standards of Reporting Trials diagram. ERCC1, excision repair cross-complementation group 1; IHC, immunohistochemistry; TS, thymidylate synthase.

Article Snippet: Immunohistochemical staining was carried out using the D6G6 anti-excision repair cross-complementation group 1 (ERCC1) monoclonal antibody (Cell Signaling Technology, Danvers, MA), the TS106 anti-TS monoclonal antibody (Dako, Glostrup, Denmark), and a DAKO Link 48 system (Dako).

Techniques: Immunohistochemistry

Journal: ESMO Open

Article Title: Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial

doi: 10.1016/j.esmoop.2021.100249

Figure Lengend Snippet: Survival outcomes according to excision repair cross-complementation group 1 (ERCC1) and thymidylate synthase (TS) expression. (A) Immunohistochemistry for TS expression in soft tissue sarcoma (STS). Representative images of both TS-negative (H-score: 0, ×200) and TS-positive (H-score: 10 and 200, ×200) sections. (B) Immunohistochemistry for ERCC1 expression in sections from patients with STS. Representative images of ERCC1-negative (H-score: 0, ×200) and ERCC1-positive sections (H-score: 15 and 200, ×200). (C) Kaplan–Meier analysis of overall survival (OS) according to TS expression, determined using a cut-off point of median H-score 25. (D) Kaplan–Meier analysis of OS according to ERCC1 expression, determined using a cut-off point of median H-score 60.

Article Snippet: Immunohistochemical staining was carried out using the D6G6 anti-excision repair cross-complementation group 1 (ERCC1) monoclonal antibody (Cell Signaling Technology, Danvers, MA), the TS106 anti-TS monoclonal antibody (Dako, Glostrup, Denmark), and a DAKO Link 48 system (Dako).

Techniques: Expressing, Immunohistochemistry